Tumor-Agnostic Precision Immunooncology And Somatic Targeting Rational For You (Tapistry) Phase II Platform Trial
Posted Date: May 5, 2021
- Investigator: Davendra Sohal
- Specialties: Cancer, Oncology
- Type of Study: Drug
The goal of this study is to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay.
Criteria:
Histologically Or Cytologically Confirmed Diagnosis Of Advanced And Unresectable Or Metastatic Solid Malignancy, Life Expectancy >= 8 Weeks, Disease Progression On Prior Treatment, Or Previously Untreated Disease With No Available Acceptable Treatment, Ecog 0-2, No Anticancer Treatment Within 2 Weeks, No History Of Or Concurrent Serious Medical Condition Or Abnormality In Clinical Laboratory Tests That, In The Investigator's Judgment, Precludes The Participant's Safe Participation In And Completion Of The Study Or Confounds The Ability To Interpret Data From The Study, No Other Malignancy Within 5 Years
Keywords:
Phase Ii, Immunooncology
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com